Analyzing enGene (NASDAQ:ENGN) & Rezolute (NASDAQ:RZLT)

Rezolute (NASDAQ:RZLT) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Rezolute has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500.

Profitability

This table compares Rezolute and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
enGene	N/A	-56.06%	-45.64%

Earnings & Valuation

This table compares Rezolute and enGene”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41 million	($0.82)	-5.59
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.84

Rezolute is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Rezolute and enGene, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1	3	8	0	2.58
enGene	2	8	4	0	2.14

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 104.69%. enGene has a consensus target price of $11.05, suggesting a potential upside of 506.89%. Given enGene’s higher possible upside, analysts clearly believe enGene is more favorable than Rezolute.

Summary

Rezolute beats enGene on 7 of the 11 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.